110 / 160
662
Monoclonal Antibody, Administered Throughout Pregnancy
and Lactation, on the Development of the Macaque Immune
System. Am J Reprod Immunol. agosto de 2007;58(2):138-49.
91. Schnitzler F, Fidder H, Ferrante M, Ballet V, NomanM, Van Assche
G, et al. Outcome of pregnancy in women with inflammatory
bowel disease treated with antitumor necrosis factor therapy.
Inflamm Bowel Dis. 6 de enero de 2011;17(9):1846-54.
92. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein
GR. Outcome of Pregnancy in Women Receiving Infliximab for
the Treatment of Crohn’s Disease and Rheumatoid Arthritis. Am
J Gastroenterol. diciembre de 2004;99(12):2385-92.
93. Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, ALLEZ M, et
al. Factors associated with pregnancy outcome in anti-TNF
treated women with inflammatory bowel disease. Aliment
Pharmacol Ther. 30 de junio de 2014;40(4):363-73.
94. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A Safety
Assessment of Tumor Necrosis Factor Antagonists During
Pregnancy: A Review of the Food and Drug Administration
Database. J Rheumatol. 13 de marzo de 2009;36(3):635-41.
95. Crijns HJMJ, Jentink J, Garne E, Gispen-de Wied CC, Straus
SMJM, de Jong-van den Berg LTW, et al. The distribution of
congenital anomalies within the VACTERL association among
tumor necrosis factor antagonist-exposed pregnancies is
similar to the general population. J Rheumatol. septiembre de
2011;38(9):1871-4.
96. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report:
Fatal case of disseminated BCG infection in an infant born to a
mother taking infliximab for Crohn’s Disease. Journal of Crohn’s
and Colitis. noviembre de 2010;4(5):603-5.
97. Yarur A, Kane SV. Update on pregnancy and breastfeeding in
the era of biologics. Digestive and Liver Disease. octubre de
2013;45(10):787-94.
98. Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P.
Infliximab and semen quality in men with inflammatory bowel
disease. Inflamm Bowel Dis. abril de 2005;11(4):395-9.
99. Puchner R, Danninger K, Puchner A, Pieringer H. Impact of
TNF-blocking agents on male sperm characteristics and
pregnancy outcomes in fathers exposed to TNF-blocking agents
at time of conception. Clin Exp Rheumatol. septiembre de
2012;30(5):765-7.
100. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes
R, et al. Mechanism of action of certolizumab pegol (CDP870):
In vitro comparison with other anti-tumor necrosis factor
α
agents. Inflamm Bowel Dis. 2007;13(11):1323-32.
101. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel
CA, et al. Placental Transfer of Anti–Tumor Necrosis Factor
Agents in Pregnant Patients With Inflammatory Bowel
Disease. Clin Gastroenterol Hepatol. Elsevier Inc; 1 de marzo
de 2013;11(3):286-92.
102. PIANO: A 1000 Patient Prospective Registry of Pregnancy
Outcomes in Women With IBD Exposed to Immunomodulators
and Biologic Therapy. 15 de diciembre de 2012;:1–1.
103. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/
fetal development in cynomolgus monkeys exposed to
natalizumab, an
α
4
integrin inhibitor. Birth Defects Research
Part B: Developmental and Reproductive Toxicology. abril de
2009;86(2):117-30.
104. Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J. Effects
of natalizumab, an
α
4
integrin inhibitor, on fertility in
male and female guinea pigs. Birth Defects Research Part
B: Developmental and Reproductive Toxicology. abril de
2009;86(2):108-16.
105. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab:
results of an observational study in 35 accidental pregnancies
during natalizumab treatment. Multiple Sclerosis Journal. 15
de julio de 2011;17(8):958-63.
106. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F,
Sands BE, et al. Vedolizumab as Induction and Maintenance
Therapy for Crohn’s Disease. N Engl J Med. 22 de agosto de
2013;369(8):711-21.
107. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel
J-F, Sandborn WJ, et al. Vedolizumab as Induction and
Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 22
de agosto de 2013;369(8):699–710.
[REV. MED. CLIN. CONDES - 2015; 26(5) 649-662]